Expression of death receptor-3 in human breast cancer and its functional effects on breast cancer cells in vitro

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1356-1364

  Ge, Zhicheng ^a,b   Sanders, Andrew J ^a   Ye, Lin ^a   Mansel, Robert E ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Death receptor 3; Migration; Prognosis; Survival

Indexed keywords

DEATH RECEPTOR 3; RIBOZYME;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CELL LINE; CELL MIGRATION; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TARGETING; GENE TECHNOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TRANSGENE;

BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; SURVIVAL RATE;

EID: 84874684327     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2259     Document Type: Article

References (22)

1. Zhai Y, Ni J, Jiang GW, et al: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189, 1999.
2. Migone TS, Zhang J, Luo X, et al: TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16: 479-492, 2002.
3. Zhang N, Sanders AJ, Ye L and Jiang WG: Vascular endothelial growth inhibitor in human cancer (Review). Int J Mol Med 24: 3-8, 2009.
4. Muppidi JR, Tschopp J and Siegel RM: Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21: 461-465, 2004.
5. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501, 2001.
6. Kitson J, Raven T, Jiang YP, et al: A death-domain-containing receptor that mediates apoptosis. Nature 384: 372-375, 1996.
7. Chinnaiyan AM, O'Rourke K, Yu GL, et al: Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274: 990-992, 1996.
8. Wen L, Zhuang L, Luo X and Wei P: TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem 278: 39251-39258, 2003.
9. Marsters SA, Sheridan JP, Donahue CJ, et al: Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol 6: 1669-1676, 1996.
10. Haridas V, Shrivastava A, Su J, et al: VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18: 6496-6504, 1999.
11. Gout S, Morin C, Houle F and Huot J: Death receptor-3, a new E-Selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation. Cancer Res 66: 9117-9124, 2006.
12. Porter PL: Global trends in breast cancer incidence and mortality. Salud Publica Mex 51 (Suppl 2): 141-146, 2009.
13. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K and Mansel RE: Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 11: 781-791, 2004.
14. Zuker M: Mfold web server for nucleic acid folding and hybrid¬ization prediction. Nucleic Acids Res 31: 3406-3415, 2003.
15. Jiang WG, Davies G and Fodstad O: Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection. Biochem Biophys Res Commun 330: 253-262, 2005.
16. Sanders AJ, Parr C, Mason MD and Jiang WG: Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med 20: 613-619, 2007.
17. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L and Mansel RE: Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 7: 71, 2008.
18. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE and Puntis MC: Regulation of the expression of E-cadherin on human cancer cells by gamma-linolenic acid (GLA). Cancer Res 55: 5043-5048, 1995.
19. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF and Puntis MC: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. Br J Cancer 71: 744-752, 1995.
20. Jiang WG, Hiscox SE, Parr C, et al: Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. Clin Cancer Res 5: 3695-3703, 1999.
21. Parr C, Gan CH, Watkins G and Jiang WG: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81, 2006.
22. Zhai Y, Yu J, Iruela-Arispe L, et al: Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82: 131-136, 1999.